Bristol Myers’ US/UK List Price Parity Plan For Cobenfy Leverages Trump’s MFN Concerns

 
• By Kevin Grogan and Cathy Kelly
  
Ex-US price negotiations likely will include reference to the MFN benchmark going forward. (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Pricing Debate

More from United States